Keyphrases
Finland
100%
Preeclampsia
85%
Nationwide Registers
63%
Register Study
56%
Confidence Interval
50%
Gestational Diabetes
49%
High-risk Human Papillomavirus (HR-HPV)
39%
Ovarian Cancer
35%
During Pregnancy
34%
Hypertensive Disorders of Pregnancy
32%
ENGOT
29%
Adjusted Odds Ratio
25%
Mode of Delivery
25%
Fear of childbirth
24%
Meta-analysis
23%
Risk Factors
22%
Labor Analgesia
20%
Register-based Analysis
19%
Puerperium
19%
Genome-wide Association Study
18%
Pregnant Women
18%
Medical Birth Register
17%
Overall Survival
16%
PARP Inhibitor (PARPi)
15%
Traumatic Brain Injury
15%
Gestational Diabetes Mellitus
15%
Adverse Pregnancy Outcomes
15%
JC Polyomavirus (JCPyV)
14%
TOLAC
14%
BK Polyomavirus (BKPyV)
14%
Frozen Embryo Transfer
14%
Systematic Meta-analysis
14%
Epithelial Ovarian Cancer
14%
Recurrent Endometrial Cancer
14%
Dostarlimab
14%
Odds Ratio
14%
Placebo
14%
Second Pregnancy
14%
Body Mass Index
14%
Homologous Recombination Deficiency
13%
National Cohort Study
13%
Pregnancy Complications
13%
Blood Pressure
12%
Progression-free Survival
11%
Ovarian Cancer Patients
11%
Bleeding
11%
Previous Cesarean Section
11%
Prospective Cohort Study
11%
Tumor
11%
Randomized Controlled Trial
11%
Early childhood
11%
Vaginal Birth
11%
Papillomavirus Infections
10%
FinnGen
10%
Residual Disease
10%
Tampere
10%
Finnish Women
10%
Obesity
10%
Induction of Labor
10%
Fetal Outcome
10%
Neonatal Outcome
10%
Randomized Placebo-controlled Trial
10%
Ischemic Stroke
10%
Chemotherapy
9%
Multicenter Trial
9%
Bleeding Risk
9%
Thrombosis Risk
9%
Clinical Evaluation
9%
Developmental Dysplasia of the Hip
9%
Subsequent Pregnancy
9%
Collagen Production
9%
Pelvic Organ Prolapse
9%
Poly(L-lactide-co-ε-caprolactone)
9%
Ascorbic Acid 2-phosphate
9%
Colposcopy
9%
12-year-olds
9%
Birth Rate
9%
Child Neurodevelopment
9%
Birth Outcomes
9%
Postpartum Hemorrhage
9%
HPV16
9%
Bevacizumab
9%
Nulliparous Women
9%
Preterm Delivery
9%
Early Pregnancy
9%
Gestational Week
8%
Type 2 Diabetes Mellitus (T2DM)
8%
Stromal Cells
8%
Etiology
8%
Hazard Ratio
8%
First Pregnancy
8%
Antibody Level
8%
University Hospital
8%
Week of Gestation
7%
Preterm Birth
7%
Cesarean Section (C-section)
7%
Endometrial Cancer
7%
Serology
7%
Corpus Luteum
7%
Retrospective Cohort Study
7%
Medicine and Dentistry
Pre-Eclampsia
66%
Cohort Analysis
64%
Ovarian Cancer
50%
Cesarean Section
40%
Odds Ratio
37%
Disease
32%
Gestational Diabetes
29%
Fear of Childbirth
24%
Obstetric Analgesia
20%
Wart Virus
19%
Pelvic Organ Prolapse
19%
Puerperium
19%
Neoplasm
17%
PARP Inhibitor
17%
Vaginal Delivery
17%
Retrospective Cohort Study
16%
Biological Marker
16%
Randomized Controlled Trial
16%
Meta-Analysis
15%
Apoplexy
15%
Overall Survival
15%
Krukenberg Tumor
15%
Traumatic Brain Injury
15%
Chorioamnionitis
15%
Embryo Transfer
14%
Uterine Cancer
14%
Nulliparous
14%
Bleeding
13%
Body Mass Index
13%
Blood Pressure
12%
Arm
12%
Diseases
12%
Pregnancy Complication
11%
Pregnancy
11%
Olaparib
11%
Gestational Hypertension
11%
Premature Labor
11%
Clinical Trial
11%
Bevacizumab
11%
Prospective Cohort Study
11%
Systematic Review
10%
Minimal Residual Disease
10%
Logistic Regression Analysis
10%
Birth Rate
10%
Offspring
10%
Progression Free Survival
10%
Brain Ischemia
10%
Obesity
10%
Neonatal Infant
10%
Venous Thromboembolism
9%
Thrombosis
9%
Dysplasia
9%
Ascorbic Acid 2 Phosphate
9%
Mental Health
9%
Nerve Cell Differentiation
9%
Birth Outcomes
9%
Female Genital Tract Cancer
9%
Uterine Cervix Ripening
9%
Homologous Recombination
9%
Analgesia
9%
Trial of Labor
9%
Malignant Neoplasm
8%
Human Papillomavirus Type 16
8%
Stromal Cell
8%
Pelvis
8%
Epidural Analgesia
8%
Labor Onset
7%
Twin Pregnancy
7%
Cervical Cancer
7%
Labor Induction
7%
Placebo
7%
Umbilical Artery
7%
Hazard Ratio
7%
Health Care
7%
Tissue Regeneration
6%
Corpus Luteum
6%
Genome Wide Association Study
6%
Intrapartum
6%
Arterial Stiffness
6%
Recurrent Disease
6%
Uterine Contraction
6%
Cerebral Hemorrhage
6%
Birth Weight
6%
Cervical Cancer Screening
6%
Stress Incontinence
6%
Serositis
6%
Colposcopy
6%
Oral Glucose Tolerance Test
6%
Small for Gestational Age
6%
Cardiovascular System
5%
Immunity
5%
Anthropometry
5%
Methylation
5%
Vaginal Birth after Cesarean
5%
Case-Control Study
5%
Cytotechnology
5%
Instrumental Delivery
5%
Reproductive Public Health
5%
Prognostic Factor
5%
Oncology
5%